{"id":14405,"date":"2021-07-01T12:11:38","date_gmt":"2021-07-01T11:11:38","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=14405"},"modified":"2021-10-11T13:37:39","modified_gmt":"2021-10-11T12:37:39","slug":"biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/","title":{"rendered":"bioM\u00e9rieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL\u00ae Rapid AST system in Europe"},"content":{"rendered":"\n<p>Article released on <a href=\"https:\/\/specificdx.com\/wp-content\/uploads\/2021\/06\/PR-bioMerieux-and-Specific-Diagnostics-agreement-20210629.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">SPECIFIC website<\/a> on June 29, 2021<\/p>\n\n\n\n<p>Marcy l\u2019\u00c9toile, France and Mountain View, California \u2013 June 29th, 2021<\/p>\n\n\n<p>bioM\u00e9rieux, a world leader in the field of in vitro diagnostics, and Specific Diagnostics, a company bringing unique in vitro diagnostic systems to clinical microbiology, announce that bioM\u00e9rieux will distribute Specific Diagnostics\u2019 newly introduced REVEAL Rapid AST system in Europe.In the context of the global threat from Antimicrobial Resistance (AMR), clinicians need to receive faster antibiotic susceptibility test (AST) results and accurate interpretation, to enable timely and optimized patient intervention.<\/p>\n<p>In bloodstream infections, an urgent and often life-threatening condition, time is of the essence to deliver targeted antibiotic treatment: it is crucial to determine what antibiotic to prescribe, at which dose, for what duration. Making clinical decisions based on rapid AST not only dramatically improves patient outcomes, but also serves the broader purpose of fighting Antimicrobial Resistance, to help sustain the efficacy of antibiotics for generations to come.<\/p>\n<p>A perfect complement to bioM\u00e9rieux\u2019s suite of systems delivering rapid results Developed by Specific Diagnostics, and based on its unique, patented metabolomic signature technology, the REVEAL Rapid AST system provides actionable results for bloodstream infections (in an average of 5 hours* directly from positive blood culture), allowing either timely de-escalation to a focused, more appropriate and lower-cost therapy, or life-saving rapid escalation to a more effective drug where a multidrugresistant (MDR) infection is present.<\/p>\n<p>REVEAL Rapid AST offers customers an easy to use instrument with a targeted menu, small footprint, and modular design well-suited for a large number of hospitals. REVEAL Rapid AST system is a perfect complement to bioM\u00e9rieux\u2019s unique suite of systems delivering rapid results including the industry\u2019s fastest blood culture system, the BACT\/ALERT\u00ae VIRTUO\u00ae, and rapid identification with either VITEK\u00ae MS PRIME or BIOFIRE\u00ae BCID2, and VITEK\u00ae 2.<\/p>\n<p>Adding REVEAL Rapid AST enables hospitals to have the fastest possible path to fully actionable results, combining ID (microbial identification) and AST, to allow clinicians to diagnose and treat patients much faster, establishing a new standard of care.<\/p>\n<p>Mark Miller, Executive Vice President, Chief Medical Officer, bioM\u00e9rieux explained: \u201cPartnering with a fast AST solution makes great sense for bioM\u00e9rieux, whose mission over decades is to provide diagnostic solutions that support the best possible patient care. By combining the advanced technology of the REVEAL Rapid AST solution for bloodstream infections with our own solutions, we are increasing the ability of laboratories to deliver results in record time, especially in cases of very critical infections such as sepsis, which require urgent and appropriate treatment.\u201d<\/p>\n<p><strong>A distribution agreement within a stronger partnership<\/strong><\/p>\n<p>The co-exclusive distribution agreement signed between both companies will cover Europe, where the REVEAL Rapid AST has been CE-IVD approved. In addition, bioM\u00e9rieux will invest 10M$ thru a Convertible Promissory Note to support commercial activities. In 2019, bioM\u00e9rieux participated in Specific Diagnostics\u2019 Series A funding&nbsp; round, alongside other investors. As a result of this transaction, bioM\u00e9rieux holds around 8% of the share capital of Specific Diagnostics.<\/p>\n<p>\u201cWe are honored to partner with a world leader as bioM\u00e9rieux to bring the REVEAL Rapid AST system to microbiology labs across Europe,\u201d said Paul A. Rhodes, Ph.D., CEO of Specific. \u201cEvery lab we encounter wants rapid, easy-to-use susceptibility testing at the right price; we couldn\u2019t reach them all without partnering with an organization with the scale and quality of bioM\u00e9rieux.\u201d<\/p>\n<p>Pierre Boulud, Chief Operating Officer, Clinical Operations, bioM\u00e9rieux declared: &#8220;With the addition of Specific Diagnostics\u2019 REVEAL Rapid AST system into its microbiology offer, bioM\u00e9rieux demonstrates its commitment to provide fast AST to clinicians and laboratories, with the double objective of dramatically improving patient outcomes and serving antimicrobial stewardship, leveraging our extensive distribution network.\u201d<br>* Tibbetts et al, ECCMID 2020 and in review.<\/p>\n<p>ABOUT BIOM\u00c9RIEUX\u2019S COMPLETE ANTIMICROBIAL STEWARDSHIP (AMS) SOLUTION<br>bioM\u00e9rieux\u2019s healthcare mission is to help sustain the use of antibiotic efficacy for generations to come. To support hospitals, institutions and laboratories with their AMS programs, bioM\u00e9rieux has a complete solution covering antibiotic therapy initiation, optimization and discontinuation. This constantly evolving offer provides timely, accurate results to adjust therapy, transforms data into actionable insights and integrates smoothly into any hospital with its flexible partnership approach. bioM\u00e9rieux has over 55 years of microbiology expertise with 80% of its R&amp;D directed to AMR\/AMS research to ensure the current offer evolves to meet customers\u2019 AMS needs.<\/p>\n<p>ABOUT BIOM\u00c9RIEUX<br>Pioneering Diagnostics<br>A world leader in the field of in vitro diagnostics for over 55 years, bioM\u00e9rieux is present in 44 countries and serves more than 160 countries with the support of a large network of distributors. In 2020, revenues reached \u20ac3.1 billion, with over 90% of sales outside of France.<\/p>\n<p><a href=\"https:\/\/www.biomerieux.com\" target=\"_blank\" rel=\"noopener\">bioM\u00e9rieux<\/a> provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agrifood, pharmaceutical and cosmetic products.<\/p>\n<p>ABOUT SPECIFIC DIAGNOSTICS<br><a href=\"http:\/\/www.specificdx.com\" target=\"_blank\" rel=\"noopener\">Specific Diagnostics<\/a> has developed in vitro diagnostic systems based upon a unique, patented metabolomic signature technology that enables rapid detection and identification of microorganisms as they grow in culture. Its first commercial application, the REVEAL\u00ae, applies this fundamental new capability to the rapid determination of antimicrobial susceptibility directly from positive blood cultures, as well as isolate dilutions. Specific is based in Mountain View, CA with operations in the UK, France and Ireland.<\/p>","protected":false},"excerpt":{"rendered":"<p>Article released on SPECIFIC website on June 29, 2021 Marcy l\u2019\u00c9toile, France and Mountain View, California \u2013 June 29th, 2021 bioM\u00e9rieux, a world leader in the field of in vitro diagnostics, and Specific Diagnostics, a company bringing unique in vitro diagnostic systems to clinical microbiology, announce that bioM\u00e9rieux will distribute Specific Diagnostics\u2019 newly introduced REVEAL [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":14427,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>bioM\u00e9rieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL\u00ae Rapid AST system in Europe - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"bioM\u00e9rieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL\u00ae Rapid AST system in Europe - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-01T11:11:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-11T12:37:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/07\/Bloodtest.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"562\" \/>\n\t<meta property=\"og:image:height\" content=\"561\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"bioM\u00e9rieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL\u00ae Rapid AST system in Europe\",\"datePublished\":\"2021-07-01T11:11:38+00:00\",\"dateModified\":\"2021-10-11T12:37:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/\"},\"wordCount\":924,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/07\/Bloodtest.jpg\",\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/\",\"name\":\"bioM\u00e9rieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL\u00ae Rapid AST system in Europe - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/07\/Bloodtest.jpg\",\"datePublished\":\"2021-07-01T11:11:38+00:00\",\"dateModified\":\"2021-10-11T12:37:39+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/07\/Bloodtest.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/07\/Bloodtest.jpg\",\"width\":562,\"height\":561,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infos pratiques &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Actualit\u00e9s\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"bioM\u00e9rieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL\u00ae Rapid AST system in Europe\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"bioM\u00e9rieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL\u00ae Rapid AST system in Europe - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/","og_locale":"fr_FR","og_type":"article","og_title":"bioM\u00e9rieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL\u00ae Rapid AST system in Europe - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2021-07-01T11:11:38+00:00","article_modified_time":"2021-10-11T12:37:39+00:00","og_image":[{"width":562,"height":561,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/07\/Bloodtest.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"\u00c9milie Noguez","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"bioM\u00e9rieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL\u00ae Rapid AST system in Europe","datePublished":"2021-07-01T11:11:38+00:00","dateModified":"2021-10-11T12:37:39+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/"},"wordCount":924,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/07\/Bloodtest.jpg","articleSection":["Actualit\u00e9s"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/","name":"bioM\u00e9rieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL\u00ae Rapid AST system in Europe - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/07\/Bloodtest.jpg","datePublished":"2021-07-01T11:11:38+00:00","dateModified":"2021-10-11T12:37:39+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/07\/Bloodtest.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/07\/Bloodtest.jpg","width":562,"height":561,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/biomerieux-and-specific-diagnostics-announce-a-co-exclusive-distribution-agreement-for-the-specific-reveal-rapid-ast-system-in-europe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Infos pratiques &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/"},{"@type":"ListItem","position":3,"name":"Actualit\u00e9s","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/"},{"@type":"ListItem","position":4,"name":"bioM\u00e9rieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL\u00ae Rapid AST system in Europe"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-15 08:43:39","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/14405"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=14405"}],"version-history":[{"count":30,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/14405\/revisions"}],"predecessor-version":[{"id":17697,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/14405\/revisions\/17697"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media\/14427"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=14405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=14405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=14405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}